Xuanzhu Biopharmaceutical Co., Ltd. Class H
HHKEX:25758.30
HKD
-0.26
(-3.04%)
ISIN
CNE1000074Q1
Return %
Stock
S&P 500
1Y
-86.17
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yan Jun Xu
- Full Time Employees
- 342
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 2107, Building 2 Beijing BE China
- IPO Date
- Oct 15, 2025
- Website
- xuanzhubio.com
- Similar Companies
- Business
- Xuanzhu Biopharmaceutical Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products primarily focused on chemical and biological drugs. Its core product portfolio includes small molecule chemical drugs, monoclonal antibodies, bispecific antibodies, and antibody conjugated drugs. The company targets therapeutic areas such as gastrointestinal diseases, oncology (including breast cancer and colorectal cancer), and non-alcoholic steatohepatitis (NASH). Xuanzhu offers proprietary innovative drug candidates including KBP-3571, XZP-3287, XZP-3621, as well as licensed products like NG-350A for oncology treatment in Greater China. The company operates mainly in China and Hong Kong and is headquartered in Shijiazhuang, China. Founded in 2008, it is a subsidiary of Beijing-based Sihuan Pharmaceutical Holdings Group Ltd. Recent major developments include the company's successful initial public offering on the Hong Kong Stock Exchange in October 2025 (Ticker: 2575.HK), with strong market performance following the IPO. Xuanzhu Biopharmaceutical has implemented a strategic growth approach termed “Dual-Wheel Drive + Three Commercialization Pillars,” focusing heavily on its core clinical pipeline and expanding product commercialization. In September 2025, the company acquired Beijing Combio Pharmaceutical, enhancing its biologics pipeline with two antibody technology platforms. Notably, Xuanzhu's NG-350A product, licensed from Akamis, received Fast Track designation by the U.S. FDA for advanced rectal cancer treatment, signaling international regulatory progress. The company also recently presented important Phase III clinical trial data on pyrotinib and other candidates at major oncology conferences, reinforcing its leadership in oncology drug development. Additionally, Xuanzhu approved a full H-share conversion plan to consolidate its share structure and enhance equity liquidity. The company continues to invest heavily in R&D, with significant budget allocations for the development of both its core and key pipeline products. Overall, Xuanzhu Biopharmaceutical operates within the innovative biopharmaceutical industry, targeting both domestic Chinese and broader Greater China markets with a strong emphasis on advanced oncology and digestive disease therapies, supported by recent strategic acquisitions, regulatory milestones, and market initiatives shaping its growth trajectory.